Disruptive Technologies in Pharma 2020

SMi Group 20 - 21 January 2020, London, UK.
The conference aims to bring together experts of emerging technologies to discover the opportunities with regards to Artificial intelligence, Machine Learning, Internet of Things, Digital therapeutics, eHealth and blockchain. The effect of these technologies on the industry will be discussed with the aim to highlight challenges related to the implementation of these new technologies and to discuss how to overcome them.

Industry case studies will reveal personal experiences and strategies to approaching digitalization, providing a benchmark for practice and improving understanding of forecasts until 2020.

Transformations require regulatory adjustments therefore, the conference will also feature insights into new regulatory guidelines and standards of practice, with special focus on the new class of drugs called digital therapeutics, to provide a complete picture of every aspect of the transformation process.

Network and learn from leading professionals such as Vice Presidents, Directors Managers and Heads of: Emerging/Disruptive Technologies, Artificial Intelligence, Machine Learning, Data Science/Analytics, Technology, External and Internal Innovation, Digital IoT and Bioinformatics.

Chairs for 2020

  • Karl Hess, Managing Director, OnDigitalHealth Consulting

Featured Speakers include

  • Mark Campbell, Freelance Regulatory Expert, former NICE
  • Vladimir Anisimov, Principal Data Scientist, Amgen
  • Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis

For more information and to register, plase visit www.disruptivetech-pharma.com/WPN

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...